Pharming Group NV
Pharming is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products.

Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA).

The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage).

LATEST NEWS

April 23, 2008
Pharming Starts Clinical Program In Ageing Diseases ... [ NL versie ]

April 18, 2008
Pharming Announces First Quarter 2008 Results ... [ NL versie ]

April 16, 2008
Pharming Provides Update On Business-strategy At Shareholders Meeting ... [ NL versie ]